NCT01019603View on ClinicalTrials.gov

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 12, 2009

Primary Completion Date

December 20, 2009

Study Completion Date

December 20, 2009

Conditions

Acne Vulgaris

Interventions

DRUG

Tazarotene

Topical Tazarotene foam applied daily for 22 days.

DRUG

Tazaroc Gel

Topical tazarotene gel applied daily for 22 days.

Trial Locations (1)

78759

DermResearch, Inc., Austin

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Stiefel, a GSK Company

INDUSTRY

NCT01019603 - A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris | Biotech Hunter | Biotech Hunter